Topical treatment for atopic dermatitis
This study is testing if teaching patients the right way to use a cream for atopic dermatitis can help them stick to their treatment better and improve their skin condition.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 9 Years and up |
| Sex | All |
| Sponsor | Wake Forest University Health Sciences Academic / other |
| Locations | 1 site (Winston-Salem, North Carolina) |
| Trial ID | NCT06244212 on ClinicalTrials.gov |
What this trial studies
This study investigates the impact of a brief educational demonstration on the proper application of topical medication, specifically triamcinolone cream, for patients with atopic dermatitis. Participants will be divided into two groups: one receiving the educational intervention and the other serving as a control group. The goal is to assess the differences in medication adherence and treatment outcomes based on the amount of medication dispensed. The study aims to address the significant issue of non-adherence to topical treatments, which can lead to treatment failure and increased healthcare costs.
Who should consider this trial
Good fit: Ideal candidates include individuals aged over 9 with a diagnosis of skin dermatitis who can return for a one-week follow-up.
Not a fit: Patients without a diagnosis of skin dermatitis or those with less than 2% body surface area affected may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve medication adherence and treatment outcomes for patients with atopic dermatitis.
How similar studies have performed: Previous studies have shown that standardized dosing in topical treatments can significantly improve patient outcomes, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of skin dermatitis * Age \> 9 * Ability to return for a one-week clinical studies follow-up * Patients who are candidates for treatment with 0.1% triamcinolone ointment (even if they weren't in the study) * Adult or pediatric patients with active dermatitis who receive dermatologic care at Atrium Health Wake Forest Baptist, Department of Dermatology. Exclusion Criteria: * Patients without the diagnosis of skin dermatitis * Inability to return for a one week follow up appointment * Body Surface Area (BSA) affected \<2%
Where this trial is running
Winston-Salem, North Carolina
- Wake Forest University Health Sciences — Winston-Salem, North Carolina, United States (Recruiting)
Study contacts
- Principal investigator: Steven R Feldman, MD, PhD — Wake Forest University Health Sciences
- Study coordinator: Irma Richardson, MHA
- Email: irichard@wakehealth.edu
- Phone: 336.716.2903
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.